Brief: Biofrontera Q1 EBITDA At EUR 1.3 Mln

Biofrontera AG

17/05/2022 15:45

May 17 (Reuters) - BIOFRONTERA AG  B8FGn.DE :
    * PUBLISHES ITS RESULTS FOR FIRST THREE MONTHS ENDED MARCH
31,
2022
    * Q1 REVENUE FOR PERIOD FROM JANUARY 1 TO MARCH 31, 2022 WAS
TEUR
6,566, APPROXIMATELY 20% HIGHER THAN REVENUE IN PRIOR-YEAR
PERIOD OF TEUR 5,479
    * Q1 GENERATED SALES WITH FORMER SUBSIDIARY BIOFRONTERA INC.
IN Q1
IN AMOUNT OF TEUR 4,761, COMPARED TO TEUR 3,811 IN SAME PERIOD
OF PREVIOUS YEAR (+25%)
    * Q1 CASH AND CASH EQUIVALENTS IN GROUP AMOUNTED TO TEUR
4,918 AS
OF MARCH 31, 2022
    * CONFIRMS FORECAST FOR 2022 FINANCIAL YEAR SPECIFIED ON
APRIL 29,
2022
    * OUTLOOK 2022: EXPECTS ANNUAL SALES OF EUR 24 TO 27 MILLION
AS
WELL AS AN ALMOST BREAK-EVEN EBITDA IN 2022 AND A NEGATIVE EBIT
IN LOW SINGLE-DIGIT MILLION RANGE
    * Q1 EBITDA AND EBIT AT EUR 1.3 MILLION AND EUR 1.1 MILLION,
RESPECTIVELY

Source text for Eikon:  ID:nPexC5gqma 
Further company coverage:  B8FGn.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))